I. intended use




Дата канвертавання27.04.2016
Памер110.08 Kb.

BD Viper™ System with XTR™ Technology

CLSI Laboratory Procedure*



I. INTENDED USE

The BD ProbeTec™ Trichomonas vaginalis (TV) Qx Amplified DNA Assay (TV Qx Assay), when tested with the BD Viper™ System in Extracted Mode, uses Strand Displacement Amplification technology for the direct, qualitative detection of Trichomonas vaginalis DNA in clinician-collected female endocervical swab specimens, patient-collected vaginal swab specimens (in a clinical setting), and female urine specimens. The assay is indicated for use with asymptomatic and symptomatic females to aid in the diagnosis of trichomoniasis.



II. SUMMARY AND EXPLANATION

Vaginal infections caused by Trichomonas vaginalis are among the most common conditions transmitted sexually.1 It is estimated that in the United States 7.4 million new cases of trichomoniasis appear annually compared with 3 million cases of chlamydia and 718,000 cases of gonorrhea.2 Despite being a readily diagnosed and treatable sexually transmitted disease, trichomoniasis is not a reportable infection, and control of the infection has received relatively little emphasis from public health STD control programs.3

Trichomoniasis is caused by the parasitic protozoan Trichomonas vaginalis. The infection causes some women to have symptoms which are characterized by a diffuse, malodorous, yellow-green vaginal discharge with vulvar irritation. The infection may cause discomfort during intercourse and urination, as well as irritation and itching of the female genital area. The genital inflammation caused by trichomoniasis can increase a woman’s susceptibility to HIV infection if she is exposed to the virus. Having trichomoniasis may increase the chance that an HIV-infected woman passes HIV to her sex partner(s).4 Infected women may have minimal or no symptoms of the disease. Because of this, screening for T. vaginalis in women can be considered in those at high risk for infection (i.e., women who have new or multiple partners, have a history of STDs, exchange sex for payment, and use injection drugs).5

Today, a commonly used test for a patient presenting with symptoms of vaginitis is the wet mount. This is an easy to perform test that affords several results for the clinician to utilize in determining the cause of the vaginitis symptoms. Another commonly used test is culture for Trichomonas vaginalis. The sensitivity of the wet mount and TV culture under optimal conditions can range from 40 – 60%6 when compared to PCR. The wet mount result can be influenced by factors such as microscopist experience, length of time from preparation until interpretation, the ambient temperature, and the collection devices used. The wet mount result can only be interpreted as positive if the microscopist can visualize motile trichomonads. Culture performance can be influenced by the time between inoculation and incubation as well as the temperature at which the culture is stored prior to and during incubation. Trichomonads are extremely susceptible to cold temperatures and the culture can be adversely affected if allowed to become cold. Controlled room temperature of 15 – 30 °C should be maintained after inoculation of the culture but prior to incubation. One or all of these factors can contribute to the poor sensitivity of the culture method.



* This “Sample Procedure” is not indicated as a substitute for your facility procedure manual, instrument manual, or reagent labeling/package insert. This “Sample Procedure” is intended as a model for use by your facility to be customized to meet the needs of your laboratory.

For use with Package Insert: BD ProbeTec Trichomonas vaginalis (TV) Qx Amplified DNA Assays [8089063(04) 2013-11]

The BD Viper System in Extracted Mode utilizes the newly developed BD ProbeTec Trichomonas vaginalis (TV) Qx Amplified DNA Assay. Automated extraction of DNA from clinical samples occurs on the BD Viper System through BD FOX™ extraction technology that incorporates chemical lysis, followed by binding of DNA to magnetic particles, washing and elution. The system is based on simultaneous amplification and detection of target DNA using amplification primers along with a fluorescently-labeled detector probe.7,8

III. PRINCIPLES OF PROCEDURE

The BD ProbeTec TV Qx Amplified DNA Assay is designed for use with the BD ProbeTec Qx specimen collection and transport devices, applicable reagents, the BD Viper System and BD FOX™ Extraction Tubes. Female urine specimens are collected and transported as a neat urine specimen. All specimens undergo a pre-warm step in the BD Viper Lysing Heater to dissolve mucus which may be present in certain specimens and to homogenize the specimen. After cooling, the specimens are loaded onto the BD Viper System which then performs all the steps involved in extraction and amplification of target DNA, without further user intervention. The specimen is transferred to an Extraction Tube that contains ferric oxide particles in a dissolvable film and dried Extraction Control. A high pH is used to lyse the bacterial cells and liberate their DNA into solution. Acid is then added to lower the pH and induce a positive charge on the ferric oxide, which in turn binds the negatively charged DNA. The particles and bound DNA are then pulled to the sides of the Extraction Tube by magnets and the treated specimen is aspirated to waste. The particles are washed and a high pH Elution Buffer is added to recover the purified DNA. Finally, a Neutralization Buffer is used to bring the pH of the extracted solution to the optimum for amplification of the target.

The BD ProbeTec TV Qx Amplified DNA Assay is based on the simultaneous amplification and detection of target DNA using amplification primers and a fluorescently-labeled detector probe. The reagents for SDA are dried in two separate disposable microwells: the Priming Microwell contains the amplification primers, fluorescently-labeled detector probe, nucleotides and other reagents necessary for amplification, while the Amplification Microwell contains the two enzymes (a DNA polymerase and a restriction endonuclease) that are required for SDA. The BD Viper System pipettes a portion of the purified DNA solution from each Extraction Tube into a priming microwell to rehydrate the contents. After a brief incubation, the reaction mixture is transferred to a corresponding, pre-warmed amplification microwell which is sealed and then incubated in one of the two thermally controlled fluorescent readers. The presence or absence of T. vaginalis DNA is determined by calculating the peak fluorescence (Maximum Relative Fluorescent Units [MaxRFU]) over the course of the amplification process and by comparing this measurement to a predetermined threshold value. In addition to the fluorescent probe used to detect amplified T. vaginalis target DNA, a second fluorescently-labeled oligonucleotide is incorporated in each reaction. The Extraction Control (EC) oligonucleotide is labeled with a different dye than that used for detection of the T. vaginalis-specific target and is used to confirm the validity of the extraction process. The EC is dried in the Extraction Tubes and is re-hydrated upon addition of the specimen and extraction reagents.

At the end of the extraction process, the EC fluorescence is monitored by the BD Viper instrument and an automated algorithm is applied to both the EC and T. vaginalis-specific signals to report specimen results as positive, negative, or EC failure.

When analyzing the TV Qx Assay for T. vaginalis DNA, an aliquot of the eluate will be removed and transferred to a blank microwell. When analyzing for CT/GC/TV, CT/TV or GC/TV an aliquot of the eluate will be removed and transferred to the first non-TV microwell. This provides the EC result for the TV Qx Assay. The process flow requires an additional dilution step to allow for eluate transfer to the TV Qx Priming Microwell.

IV. REAGENTS

Each BD ProbeTec TV Qx Assay Reagent Pack contains:




  • BD ProbeTec TV Qx Amplified DNA Assay Priming Microwells, (12 x 96, 1152 kit or 4 x 96, 384 kit): each Priming Microwell contains approximately 123 pmol oligonucleotides, 54 pmol fluorescently labeled detector probe, 80 nmol dNTPs, with stabilizers and buffer components.




  • BD ProbeTec TV Qx Amplified DNA Assay Amplification Microwells, (12 x 96, 1152 kit or 4 x 96, 384 kit): each Amplification Microwell contains approximately 25 units of DNA polymerase and 62 units restriction enzyme, with stabilizers and buffer components.


NOTE: Each microwell pouch contains one desiccant bag.
Additional Reagents:
Control Set for the BD ProbeTec™ Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC), and Trichomonas vaginalis (TV) Qx Amplified DNA Assays: 24 TV Qx Positive Control Tubes containing approximately 2400 copies of pCTB4 and pGCINT3 and approximately 4000 copies of TVAP651 linearized plasmids in carrier nucleic acid, and 24 TV Qx Negative Controls Tubes containing carrier nucleic acid alone. The concentration of the CTB4, GCINT3, and TVAP651 plasmids are determined by UV spectrophotometry.
BD FOX Extraction Tubes: 48 strips of 8 tubes, each containing approximately 10 mg of iron oxide in a dissolvable film and approximately 240 pmol fluorescently-labeled Extraction Control oligonucleotide.
BD Viper Extraction Reagent and Lysis Trough: 12 Reagent and 12 Lysis troughs, each 4-cavity Extraction Reagent Trough contains approximately 16.5 mL Binding Acid, 117 mL Wash Buffer, 35 mL Elution Buffer, and 29 mL Neutralization Buffer with preservative; each Lysis Trough contains approximately 11.5 mL Lysis Reagent.
V. INSTRUMENT, EQUIPMENT AND SUPPLIES

Materials Provided: BD Viper Instrument, Instrument Plates, BD Viper Pipette Tips, BD Viper Tip Waste Boxes, BD Viper Amplification Plate Sealers (Black) and Seal Tool, BD Viper Lysing Heater, BD Viper Lysing Rack, BD Viper Neutralization Pouches, Specimen Tubes and Pierceable Caps for use on the BD Viper System (Extracted Mode), Qx Swab Diluent tubes, BD ProbeTec Qx Collection Kit for Endocervical or Lesion Specimens, Vaginal Specimen Transport for the BD ProbeTec Qx Amplified DNA Assays, and Urine Preservative Transport for the BD ProbeTec Qx Amplified DNA Assays. BD Viper Accessory Kit and Microwell Package for the BD Viper System.

Materials Required But Not Provided: Nitrile gloves, 3% (w/v) hydrogen peroxide*, 1% (v/v) sodium hypochlorite**, DNA AWAY™, displacement pipettes, polypropylene aerosol-resistant pipette tips capable of delivering 0.5 mL ± 0.05 mL, and serological pipettes.

* Do not use hydrogen peroxide from a bottle that has remained open for longer than 8 days.

** Prepare fresh daily.

Storage and Handling Requirements: Reagents may be stored at 2 – 33 °C. Unopened Reagent Packs are stable until the expiration date. Once a pouch is opened, the microwells are stable for 6 weeks if properly sealed or until the expiration date, whichever comes first. Do not freeze.

VI. SWAB SPECIMEN COLLECTION, STORAGE, TRANSPORT, AND PROCESSING

Endocervical Swab Specimen Collection

Endocervical swab specimens should be collected using the BD ProbeTec Qx Collection Kit for Endocervical or Lesion Specimens.



NOTE: All specimens should be obtained from the patient by appropriately trained individuals.

  1. Remove the white cleaning swab from packaging.

  2. Using the white cleaning swab, remove excess blood and mucus from the cervical os.

  3. Discard the used white cleaning swab.

  4. Remove the pink collection swab from packaging.

  5. Insert the pink collection swab into the cervical canal and rotate for 15 – 30 s.

  6. Withdraw the pink collection swab carefully. Avoid contact with the vaginal mucosa.

  7. Uncap the Qx Swab Diluent Tube.

  8. Fully insert the pink collection swab into the Qx Swab Diluent Tube.

  9. Break the shaft of the pink swab at the score mark. Use care to avoid splashing of contents of the Qx Swab Diluent Tube.

  10. Tightly recap the tube.

  11. Label the tube with patient information and date/time collected.

  12. Transport to laboratory.

Vaginal Swab Patient Collection Procedure

Vaginal swab specimens should be collected using the Vaginal Specimen Transport for the BD ProbeTec Qx Amplified DNA Assays.



NOTE: Ensure that patients read the Patient Collection Instructions before providing them with a collection kit.

  1. Wash hands with soap and water. Rinse and dry.

  2. It is important to maintain a comfortable balance during the collection procedure.

  3. Twist the cap to break the seal. Pull the cap with attached swab from the tube. Do not touch the soft tip or lay the swab down. If you touch or drop the swab tip or the swab is laid down, discard the swab and request a new vaginal swab.

  4. Hold the swab by the cap with one hand so that the swab tip is pointing toward you.

  5. With your other hand, gently spread the skin outside the vagina. Insert the tip of the swab into the vaginal opening. Point the tip toward your lower back and relax your muscles.

  6. Gently slide the swab no more than 2 inches into the vagina. If the swab does not slide easily, gently rotate the swab as you push. If it is still difficult, do not attempt to continue. Make sure the swab touches the walls of the vagina so that moisture is absorbed by the swab.

  7. Rotate the swab for 10 – 15 s.

  8. Withdraw the swab without touching the skin. Place the swab in the tube and cap securely.

  9. After collection, wash hands with soap and water, rinse, and dry.

  10. Return tube with the swab as instructed.

Table 1 provides instructions for storage and transport conditions to the laboratory and/or test site for swab specimens. The endocervical swab specimens must be stored and transported to the laboratory and/or test site within 30 days after collection if kept at 2 – 30 °C or within 180 days after collection if kept frozen at -20 °C.

Patient-collected vaginal swab specimens must be stored and transported to the laboratory and/or test site within 14 days after collection if kept at 2 – 8 °C, within 3 days if kept at 30 °C or within 180 days after collection if kept frozen at -20 °C. Patient-collected vaginal swab specimens that are expressed in Qx Swab Diluent may be stored and processed within 30 days after expression if kept at 2 – 30 °C or within 180 days after the date of expression if kept frozen at -20 °C.



Table 1: Swab Specimen Storage and Transport

Swab Specimen Type to be Processed

Endocervical Swab Specimens and Expressed Vaginal Swab Specimens

Dry Vaginal Swab Specimens

Temperature Condition for Storage and Transport to Test Site

2 - 30°C

-20°C

2 - 8°C

30°C

- 20°C

Process and Test Specimen According to Instructions

Within 30 days of collection

Within 180 days of collection

Within 14 days of collection

Within 3 days of collection

Within 180 days of collection

Swab Specimen Processing

Processing procedure for the BD ProbeTec Qx Collection Kit for Endocervical and Lesion Specimens

NOTE: If specimens are refrigerated or frozen, make sure they are brought to room temperature and mixed by inversion prior to proceeding.

  1. Using a tube layout report, place the Qx Swab Diluent Tube with black pierceable cap in order in the BD Viper Lysing rack and lock into place.

  2. Repeat step 1 for additional swab specimens.

  3. Specimens are ready to be pre-warmed.

  4. Change gloves before proceeding to avoid contamination.

Processing procedure for the Vaginal Specimen Transport for the BD ProbeTec TV Qx Amplified DNA Assays

NOTE: Wear clean gloves when handling the vaginal swab specimen. If gloves come in contact with specimen, immediately change them to prevent contamination of other specimens.

NOTE: If specimens are refrigerated or frozen, make sure they are brought to room temperature prior to expression.

  1. Label a pre-filled Qx Swab Diluent Tube for each vaginal swab specimen to be processed.

  2. Remove the cap and insert the swab specimen into the Qx Swab Diluent Tube. Mix by swirling the swab in the Qx Swab Diluent Tube for 5 – 10 s.

  3. Express the swab along the inside of the tube so that liquid runs back into the bottom of the tube.

  4. Remove the swab carefully from the Qx Swab Diluent tube to avoid splashing.

  5. Place the expressed swab back into the transport tube and discard with biohazard waste.

  6. Tightly recap the Qx Swab Diluent Tube with the black pierceable cap.

  7. Repeat steps 1 – 6 for additional swab specimens.

  8. Using the tube layout report, place the tube in order in the BD Viper Lysing Rack and lock into place.

  9. Specimens are ready to be pre-warmed.

  10. Change gloves before proceeding to avoid contamination.

VII. URINE SPECIMEN COLLECTION, STORAGE, TRANSPORT AND PROCESSING

Performance for female urine specimens has been established with urine collected in a sterile, plastic, preservative-free specimen cup (i.e., neat urine without preservatives). Performance with other collection devices has not been established.



Urine Specimen Collection

  1. The patient should not have urinated for at least 1 h prior to specimen collection.

  2. Collect the specimen in a sterile, preservative-free specimen collection cup.

  3. The patient should collect the first 20 – 60 mL of voided urine (the first part of the stream – NOT midstream) into a urine collection cup.

  4. Cap and label with patient identification and date/time collected.

Neat Urine Storage and Transport

Store and transport neat urine specimens from the collection site to the test site at 2 – 8°C and pre-warm them within 7 days of collection. Neat urine that is not refrigerated at 2 – 8°C after collection (stored at temperatures up to 30°C) must be pre-warmed and processed within 24 h of collection. Neat urine specimens may also be stored frozen at -20°C for up to 180 days prior to pre-warming. (Table 2)



Neat Urine Processing Procedure

NOTE: Wear clean gloves when handling the urine specimen. If gloves come in contact with specimen, immediately change them to prevent contamination of other specimens. If specimens are refrigerated or frozen, make sure they are brought to room temperature and mixed by inversion prior to proceeding.

  1. Label a Specimen Tube for use on the BD Viper System (Extracted Mode) with the patient identification and date/time collected.

  2. Swirl the urine cup to mix the urine specimen and open carefully.

NOTE: Open carefully to avoid spills which may contaminate gloves or the work area.

  1. Uncap the neat urine tube and use a pipette to transfer the urine specimen into the tube. The correct volume of urine has been added when the fluid level is between the purple lines on the fill window located on the label. This volume corresponds to approximately 2.0 – 3.0 mL of urine. DO NOT overfill or under fill the tube.

  2. Tighten a black pierceable cap securely on each tube.

  3. Repeat steps 1- 4 for each urine specimen. Use a new pipette or pipette tip for each sample.

  4. Using the tube layout report, place the neat urine specimens in order in the BD Viper Lysing Rack and lock into place.

  5. Specimens are ready to be pre-warmed.

  6. Change gloves before proceeding to avoid contamination.

Table 2: Urine Specimen Storage and Transport

Urine Specimen Type to be Processed

Neat Urine

Temperature Condition for Storage and Transport to Test Site

2 - 8°C

2 - 30°C

- 20°C

Process and Test Specimen According to Instructions

Within 7 days of collection*

Within 24 h of collection*

Within 180 days of collection

* Urine specimens that are refrigerated at 2 - 8°C after collection may be stored up to 7 days prior to testing. Urine specimens that are not refrigerated at 2 - 8°C after collection (stored at temperatures up to 30°C) must be tested within 24 hours.

VIII. QUALITY CONTROL

Quality control must be performed in accordance with applicable local, state and/or federal regulations or accreditation requirements and your laboratory’s standard Quality Control procedures. It is recommended that the user refer to pertinent CLSI guidance and CLIA regulations for appropriate Quality Control practices.

The Control Set for the BD ProbeTec CT/GC/TV Qx Amplified DNA Assays is provided separately. One Positive and one Negative Control must be included in each assay run and for each new reagent kit lot number. Controls must be positioned according to the BD Viper Instrument User’s Manual. The CT/GC/TV Qx Positive Control will monitor for substantial reagent failure only. The CT/GC/TV Qx Negative Control monitors for reagent and/or environmental contamination.

The CT/GC/TV Qx Positive Control comprises recombinant plasmids that contain thee SDA target regions for CT Qx, GC Qx and TV Qx Assays. The plasmids are not necessarily representative of native target DNA detected by the assay (e.g., their overall length is shorter than that of the complete gene or genomic sequence), nor are the controls representative of the specimen matrices indicated for use the assays on the BD Viper System in extracted mode. The Positive Control, when it is rehydrated by the BD Viper System, contains approximately 2400 copies per mL of pCTB4 and pGCINT3, as well as approximately 4000 copies per mL of pTVAP651 linearized plasmids. The TV Qx Negative Control comprises the same milieu as the Positive Control but without the plasmid DNA.

The Positive and Negative Control formulations are dried in separate 4.5 mL specimen tubes. A QC pair (Positive Control and Negative Control) must be logged in for each plate to be tested and for each reagent kit lot number.

The location of the microwells is shown in a color-coded plate layout screen on the LCD Monitor. The plus symbol (+) within the microwell indicates the positive QC sample. The minus symbol (-) within the microwell indicates the negative QC sample.

A QC pair must be logged in for each plate to be tested and for each reagent kit lot number. If a QC pair has not been logged in for each plate, a message box appears that prevents saving the rack and proceeding with the run until a QC pair is added.

A maximum of two QC pairs per rack is permitted. Other control materials may be added, provided they are logged in as samples.



NOTE: The BD Viper System will rehydrate the controls during the assay run. Do not attempt to hydrate the assay controls prior to loading them into the BD Viper Lysing Rack.

Running one plate on a BD Viper System:

The first two positions (A1 and B1) are reserved for the positive (A1) and negative (B1) controls, respectively. The first available position for a patient sample is C1.



Running two plates on a BD Viper System:

For plate one, the first two positions (A1 and B1) are reserved for the positive (A1) and negative (B1) controls, respectively. The first available position for a patient sample is C1. For plate two (full plate) the last two positions (G12 and H12) are reserved for the positive (G12) and negative (H12) controls, respectively.

For plate two (partial plate) the last two positions after the last patient sample are automatically assigned as the positive and negative controls, respectively.

The CT/GC/TV Qx Positive and the CT/GC/TV Qx Negative Control must test as positive and negative, respectively. If controls do not perform as expected, the run is considered invalid and results will not be reported by the instrument. If either of the controls does not provide the expected results, repeat the entire run using a new set of controls, extraction tubes, new extraction trough, new lysis trough and new microwells.

The Extraction Control (EC) oligonucleotide is labeled with a fluorescent dye and is used to confirm the validity of the extraction process. The EC is dried in the Extraction Tubes and is rehydrated by the BD Viper System upon addition of the specimen and extraction reagents. At the end of the extraction process, the EC fluorescence is monitored by the instrument and an automated algorithm is applied to both the EC and TV Qx Assay specific signals to report results as positive, negative, or EC failure.

QUALITY CONTROL PREPARATION

NOTE: Do not re-hydrate the controls prior to loading in the BD Viper Lysing Rack.


  1. Using the tube layout report, place CT/GC/TV Qx Negative Controls into the appropriate positions in the BD Viper Lysing Rack.

  2. Using the tube layout report, place CT/GC/TV Qx Positive Controls into the appropriate positions in the BD Viper Lysing Rack.

  3. Controls are ready to be pre-warmed with the specimens, if desired.

SPECIMEN PROCESSING CONTROLS

Specimen Processing Controls may be tested in accordance with the requirements of appropriate accrediting organizations. A positive Specimen Processing Control tests the entire assay system. For this purpose, known positive specimens can serve as controls by being processed and tested in conjunction with unknown specimens. Specimens used as processing controls must be stored, processed, and tested according to the package insert instructions. Specimen processing controls for T. vaginalis may be prepared in the laboratory using commercially available Gibson Laboratories Tri-Valent™ Swab Positive Control (Cat. # TVS-01).



Gibson Laboratories Processing Control Preparation:

  1. Obtain Gibson Laboratories Tri-Valent Swab Positive Control (Cat. # TVS-01) from Gibson Laboratories.

  2. Store at 2 - 8°C per manufacturer’s instructions.

  3. Remove the control swab from container and express into a Qx Swab Diluent Tube and tightly recap using a black pierceable cap.

  4. Process the controls according to the Pre-warming Procedure and then follow the Test Procedure.

IX. PRE-WARM PROCEDURE

NOTE: The pre-warm procedure must be applied to all specimens to ensure that the specimen matrix is homogenous prior to loading on the BD Viper System. Failure to pre-warm specimens may have an adverse impact on the performance of the BD ProbeTec TV Qx Assays and/or BD Viper System. Swabs and urine specimens must be pre-warmed; however, pre-warming of the controls is optional.

  1. Insert the BD Viper Lysing Rack into the BD Viper Lysing Heater.

  2. Pre-warm the specimens for 15 min at 114C  2C.

  3. Remove the Lysing Rack from the Lysing Heater and let specimens cool at room temperature for a minimum of 15 min before loading into the BD Viper instrument.

  4. Refer to the Test Procedure for testing specimens and controls.

Table 3. Post Pre-Warm Storage Conditions

Specimen Type

Temperature Condition for Storage after Pre-Warm

2 - 8°C

30°C

-20°C

Expressed Vaginal Swabs (in Qx Swab Diluent)

Within 30 days after pre-warm

Within 30 days after pre-warm

Within 180 days after pre-warm

Endocervical Swabs

Within 30 days after pre-warm

Within 30 days after pre-warm

Within 180 days after pre-warm

Neat Urine stored 30°C for 18 h

NA

NA

Within 180 days after pre-warm

Neat Urine stored 2 - 8°C

Within 7 days after pre-warm

NA

Within 30 days after pre-warm

Note: Frozen specimens must be brought to room temperature prior to pre-warming or testing.

X. TEST PROCEDURE

Refer to the BD Viper Instrument User’s Manual (Extracted Mode Operation) for specific instructions for operating and maintaining the components of the system. The optimum environmental conditions for the TV Qx Assay were found to be 18 - 27C and 20 – 85% Relative Humidity.



XI. INTEPRETATION OF TEST RESULTS

The BD ProbeTec Trichomonas vaginalis (TV) Qx Amplified DNA Assay uses fluorescent energy transfer as the detection method to test for the presence of T. vaginalis DNA in clinical specimens. All calculations are performed automatically by the BD Viper software.



The presence or absence of T. vaginalis DNA is determined by calculating the peak fluorescence (MaxRFU) over the course of the amplification process and by comparing this measurement to a predetermined threshold value. The magnitude of the MaxRFU score is not indicative of the level of organism in the specimen. If the T. vaginalis-specific signal is greater than or equal to a threshold of 125 MaxRFU, the EC fluorescence is ignored by the algorithm. If the T. vaginalis-specific signal is less than a threshold of 125 MaxRFU, the EC fluorescence is utilized by the algorithm in the interpretation of the result. If assay control results are not as expected, patient results are not reported. See the Quality Control section for expected control values. Reported results are determined as follows.

Table 4: Interpretation of Quality Control Results

Control Type

Tube Result Report Symbol

TV Qx Max RFU

QC Disposition

CT/GC/TV Qx Positive Control



125

QC Pass

CT/GC/TV Qx Positive Control



125

QC Failure

CT/GC/TV Qx Positive Control

or or

Any value

QC Failure




CT/GC/TV Qx Negative Control



125

QC Pass

CT/GC/TV Qx Negative Control



125

QC Failure

CT/GC/TV Qx Negative Control

or or or

Any value

QC Failure

CT/GC/TV Qx Negative Control



125

QC Failure

= Fail, = Extraction Transfer failure, = Liquid Level failure, = Extraction Control failure, = Error, = ROX failure

Table 5: Interpretation of Test Results for TV Qx Assay

Tube Report Result

TV Qx MaxRFU

Report

Interpretation

Result



125

T. vaginalis plasmid DNA detected by SDA.

Positive for T. vaginalis.

T. vaginalis organism viability and/or infectivity cannot be inferred since target DNA may persist in the absence of viable organisms.

Positive




125

T. vaginalis plasmid DNA not detected by SDA.

Presumed negative for T. vaginalis.

A negative result does not preclude T. vaginalis infection because results are dependent on adequate specimen collection, absence of inhibitors, and the presence of sufficient DNA to be detected.

Negative



125

Extraction Control Failure. Repeat test from initial specimen tube or obtain another specimen for testing.

T. vaginalis, if present, is not detectable.

Extraction Control Failure



Any value

Extraction Transfer Failure. Repeat test from initial specimen tube or obtain another specimen for testing.

T. vaginalis, if present, is not detectable.

Extraction Transfer Failure



Any value

Liquid Level Failure. Repeat test from initial specimen tube or obtain another specimen for testing.

T. vaginalis, if present, is not detectable.

Liquid Level Failure



Any value

Error. Repeat test from initial specimen tube or obtain another specimen for testing.

T. vaginalis, if present, is not detectable.

Error



125

ROX Channel Failure. Repeat test from initial specimen tube or obtain another specimen for testing.

T. vaginalis, if present, is not detectable.

ROX Failure

XII. MONITORING FOR THE PRESENCE OF DNA CONTAMINATION

At least monthly, the following test procedure should be performed to monitor the work area and equipment surfaces for the presence of DNA contamination. Environmental monitoring is essential to detect contamination prior to the development of a problem.



  1. For each area to be tested, use a clean collection swab from the BD ProbeTec Qx Collection Kit for Endocervical or Lesion Specimens.

  2. Dip the swab into the Qx Swab Diluent Tube and wipe the first area* using a broad sweeping motion.

  3. Fully insert the collection swab into the Qx Swab Diluent Tube.

  4. Break the shaft of the swab at the score mark. Use care to avoid splashing of contents.

  5. Tightly recap the tube using the black pierceable cap.

  6. Repeat for each desired area.

  7. After all swabs have been collected, process according to the Pre-warming Procedure and then follow the Test Procedure.

* Recommended areas to test include: Instrument deck: Pipette Tip Station Covers (2); Tube Processing Station: Tube Alignment Block and Fixed Metal Base; Deck Waste Area, Priming and Warming Heaters/Stage; Extraction Block; Plate Sealing Tool; Tip Exchange Stations (2); Instrument Exterior: Upper Door Handle; Lower Door Handle; Waste Liquid Quick Release Valve; LCD Monitor (Touchscreen); Keyboard/Scanner; Staging Area; Locking Plate and Fixed Metal Base; Accessories: Tube Lockdown cover, BD Viper Lysing Rack/Table Base; BD Viper Lysing Heater; Metal Microwell Plates; Timer; Laboratory Bench Surfaces.

If an area gives a positive result or if contamination is suspected, clean the area with fresh 1% (v/v) sodium hypochlorite, DNA AWAY, or 3% (w/v) hydrogen peroxide. Make sure the entire area is wetted with the solution and allowed to remain on the surface for at least two minutes or until dry. If necessary, remove excess cleaning solution with a clean towel. Wipe the area with a clean towel saturated with water and allow the surface to dry. Retest the area. Repeat cleaning process until negative results are obtained. If the contamination does not resolve, contact BD Technical Services for additional information.



XIII. LIMITATIONS OF THE PROCEDURE

  1. This method has been tested only with female symptomatic and asymptomatic neat urine specimens, vaginal specimens and endocervical specimens. Performance with other specimen types has not been assessed.

  2. Optimal performance of the test requires adequate specimen collection and handling. Refer to the “Specimen Collection, Storage and Transport” section of this insert.

  3. A negative test does not exclude the possibility of infection because test results may be affected by improper specimen collection, technical error, specimen mix-up, concurrent antiprotozoal therapy, or the quantity of organism in the specimen may be below the sensitivity of the test.

  4. As with many diagnostic tests, results from the BD ProbeTec Trichomonas vaginalis (TV) Qx Amplified DNA Assay should be interpreted in conjunction with other laboratory and clinical data available to the physician.

  5. The BD ProbeTec Trichomonas vaginalis (TV) Qx Amplified DNA Assay provides qualitative results. No correlation can be drawn between the magnitude of the positive assay signal (MaxRFU) and the quantity of nucleic acid in a patient sample.

  6. The Positive Control for the BD ProbeTec Trichomonas vaginalis (TV) Qx Amplified DNA Assay is used in testing for TV, therefore correct positioning of the microwell strips is important for final results reporting.

  7. The blank microwell is required to produce the EC results for the Negative Control and to verify extraction for negative specimens, therefore correct positioning of the microwell strips is important for final results reporting.

  8. Use of the BD ProbeTec Trichomonas vaginalis (TV) Qx Amplified DNA Assay is limited to personnel who have been trained in the assay procedure and the BD Viper System.

  9. Trichomonas tenax was found to cross-reactant with the TV Qx Assay at levels above 1.0 x 104 organisms/mL. T. tenax is a commensal of the oral cavity. See TV Qx Analytical Specificity for details.

  10. The performance of the BD ProbeTec Trichomonas vaginalis (TV) Qx Amplified DNA Assay has not been evaluated in pregnant women or in patients less than 18 years of age.

  11. The performance of the BD ProbeTec Trichomonas vaginalis (TV) Qx Amplified DNA Assay has not been evaluated in the presence of Dientamoeba fragilis.

XIV. AVAILABILITY

Cat. No.

Description

440724

BD Viper™ Pipette Tips, 960

441392

BD Viper™ Trash Box

441391

BD Viper™ Trash Bags

440818

BD Viper™ Trash Boxes and Bags

440974

BD Viper™ Tube Lockdown Cover

440975

BD Viper™ Lysing Heater (115V)

440976

BD Viper™ Lysing Heater (230V)

440977

BD Viper™ Lysing Rack

440984

BD Viper™ Amplification Plate Sealers (Black)

441072

BD Viper™ Liquid Waste Bottle

441074

BD Viper™ Plate Seal Tool

440752

Microwell Package for BD Viper™ System

441091

BD Viper™ System

441917

BD ProbeTecTrichomonas vaginalis (TV) Qx Amplified DNA Assay Reagent Pack, 1152 tests

443433

BD ProbeTecTrichomonas vaginalis (TV) Qx Amplified DNA Assay Reagent Pack, 384 tests

441925

Control Set for the BD ProbeTec™ CT/GV/TV Qx Amplified DNA Assays, 24 positive and 24 negative

441128

BD Viper™ Extraction Reagent and Lysis Trough, 12 Extraction Reagent Troughs and 12 Lysis Troughs

441129

BD FOX™ Extraction Tubes

441354

BD Viper™ Neutralization Pouch, 12 pouches

441357

BD ProbeTec™ Qx Collection Kit for Endocervical or Lesion Specimens, 100 units




Cat. No.

Description

441359

Caps for use on the BD Viper™ (Extracted Mode), 4 x 100

441360

Specimen Tubes and Caps for use on the BD Viper™ (Extracted Mode), 4 x 100

441361

Swab Diluent for the BD ProbeTec™ Qx Amplified DNA Assays, 2 mL x 48

441122

Vaginal Specimen Transport for BD ProbeTec™ Qx Amplified DNA Assays


The TV preparations described previously are available from:

Gibson Laboratories, LLC

1040 Manchester Street, Lexington KY 40508

800-477-4763

www.gibsonlabs.com


XV. REFERENCES


  1. Weinstock, H., S. Berman, and W. Cates Jr. 2004. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect. Sex. Reprod. Health 36(1): 6-10.

  2. Soper D. 2004. Trichomoniasis: under control or undercontrolled? Am J Obstet Gynecol. 2 190(1): 281-90.

  3. Schwebke, J. and Burgess, D. 2004. Trichomoniasis, 2004. Clinical Micro reviews, p 794-803.

  4. Centers for Disease Control and Prevention. 2011. Trichomoniasis Fact Sheet.

  5. Centers for Disease Control and Prevention. 2010. Sexually Transmitted Diseases Treatment Guidelines. MMWR
    59: RR-12.

  6. Wendel KA, Erbelding EJ, Gaydos CA, Rompalo AM. 2002. Trichomonas vaginalis polymerase chain reaction compared with standard diagnostic and therapeutic protocols for detection and treatment of vaginal trichomoniasis. Clin Infect Dis. 35(5): 576-80.

  7. Van Der Pol B, et al. 2001. Multicenter evaluation of the BD ProbeTec ET System for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in urine specimens, female endocervical swabs, and male urethral swabs.
    J. Clin. Microbiol. 39(3): 1008-16.

  8. Little, M.C., et. al. 1999. Strand Displacement Amplification and Homogeneous Real-Time Detection Incorporated in a Second-Generation DNA Probes System, BD ProbeTec ET. Clin. Chem. 45(6):777-784.

  9. Clinical and Laboratory Standards Institute. 2005. Approved Guideline M29-A3. Protection of Laboratory workers from occupationally acquired infections, 3rd ed., CLSI, Wayne, PA.

  10. Garner, J.S. 1996 Hospital Infection Control Practices Advisory Committee, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Guideline for isolation precautions in hospitals. Infect. Control Hosp. Epidemiol. 17:53-80

  11. U.S. Department of Health and Human Services. 2007. Biosafety in microbiological and biomedical laboratories, HHS Publication (CDC), 5th ed. U.S. Government Printing Office, Washington, D.C.

  12. Directive 2000/54/EC of the European Parliament and of the council of 18 September 2000 on the protection of workers from risks related to exposure to biological agents at work (seventh individual directive within the meaning of Article 16(1) of Directive 89/391/EEC). Official Journal L262, 17/10/2000, p.0021-0045.

XVI. APPROVALS

Supervisor:________________________________ Date:_________________

Manager:__________________________________ Date:_________________

Director:__________________________________ Date:_________________

Effective Date:___________________

Reviewed by:___________________________________



Package Insert Reference:

BD ProbeTec Trichomonas vaginalis (TV) Qx Amplified DNA Assays [8089063(04)] 2013-11



CLSI Revision Date: 2014/03



База данных защищена авторским правом ©shkola.of.by 2016
звярнуцца да адміністрацыі

    Галоўная старонка